Vor Biopharma’s (VOR) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Vor Biopharma (NYSE:VORFree Report) in a research report released on Friday, Benzinga reports. Wedbush currently has a $11.00 price target on the stock.

Several other equities research analysts also recently issued reports on the stock. HC Wainwright reaffirmed a buy rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Thursday, March 21st. Oppenheimer restated an outperform rating and set a $15.00 price objective (down from $17.00) on shares of Vor Biopharma in a report on Thursday, March 21st. Stifel Nicolaus reduced their target price on Vor Biopharma from $15.00 to $12.00 and set a buy rating for the company in a research note on Thursday, March 21st. Finally, JMP Securities restated a market outperform rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Friday, March 22nd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of Buy and an average target price of $12.50.

Get Our Latest Analysis on Vor Biopharma

Vor Biopharma Stock Down 0.6 %

Shares of NYSE VOR traded down $0.01 on Friday, hitting $1.70. The company had a trading volume of 235,288 shares, compared to its average volume of 288,521. Vor Biopharma has a 12-month low of $1.62 and a 12-month high of $5.70. The firm has a market capitalization of $116.04 million, a P/E ratio of -0.97 and a beta of -0.23. The business has a 50 day moving average of $1.95 and a two-hundred day moving average of $2.07.

Vor Biopharma (NYSE:VORGet Free Report) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.10. On average, sell-side analysts anticipate that Vor Biopharma will post -1.34 earnings per share for the current year.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Exchange Traded Concepts LLC grew its stake in Vor Biopharma by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 60,170 shares of the company’s stock worth $135,000 after buying an additional 15,258 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Vor Biopharma during the third quarter worth about $37,000. Acadian Asset Management LLC bought a new position in shares of Vor Biopharma during the first quarter worth about $126,000. Finally, Vanguard Group Inc. increased its holdings in shares of Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after acquiring an additional 69,436 shares during the period. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

(Get Free Report)

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

See Also

Analyst Recommendations for Vor Biopharma (NYSE:VOR)

Receive News & Ratings for Vor Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vor Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.